Avedro gets a VC on board
This article was originally published in Clinica
Executive Summary
As Avedro awaits US FDA approval of its drug-device product for treating complications from refractive surgery, the Massachusetts firm has appointed David McIntyre, a venture capitalist, to its board of directors. David McIntyre currently serves as partner for Apple Tree Partners, a healthcare venture capital firm, where he oversees operations of fund finances and medical device investments. Mr McIntyre’s medtech industry experience also includes serving as executive vice-president, chief financial officer and chief operating officer for heart assist device maker HeartWare International.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.